FrancophonIA/ELRC3.0 huggingface dataset:
English: The company that makes Prialt is carrying out a study looking at the long-term use of the medicine, looking in particular at the possibility of development of tolerance to treatment (when doses of a medicine that used to be effective become less effective over time).
Estonian: Prialti tootja viib läbi uuringut ravimi pikaajalise kasutamise kohta, uurides eelkõige, kas ravi suhtes võib välja kujuneda tolerantsus (kui varem efektiivsete raviannuste efektiivsus aja jooksul väheneb).
English: For more information about treatment with Prialt, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Prialtiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It decided that Prialt's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Komitee otsustas, et Prialti kasulikkus ületab sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Prialt was originally authorised under ‘exceptional circumstances', because, as the disease is rare, limited information was available at the time of approval.
Estonian: Esialgu kiideti Prialt heaks erandkorras, sest haigus esineb harva ja ravimi heakskiitmise ajal ei olnud piisavalt teavet.
English: This is a summary of the European public assessment report (EPAR) for Prialt.
Estonian: See on ravimi Prialt Euroopa avaliku hindamisaruande kokkuvõte.
English: Prialt must be given as a very slow continuous infusion through an intrathecal catheter (a tube inserted into the spinal canal) using an infusion pump capable of delivering an accurate amount of the medicine.
Estonian: Prialti tuleb manustada väga aeglase pideva infusioonina intratekaalse kateetri (lülisambakanalisse viidud vooliku) kaudu, kasutades infusioonipumpa, mis võimaldab manustada ravimit täpses koguses.
English: For the full list of all side effects and restrictions with Prialt, see the package leaflet.
Estonian: Prialt kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Prialt has been compared with placebo (a dummy treatment) in 589 patients with severe long-term pain in three main studies.
Estonian: Prialti võrreldi platseeboga (näiv ravim) kolmes põhiuuringus, milles osales 589 raske kroonilise valuga patsienti.
English: Prialt is a solution for infusion that contains the active substance ziconotide.
Estonian: Prialt on infusioonilahus, mis sisaldab toimeainena sikonotiidi.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Prialt.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What benefit has Prialt shown during the studies?
Estonian: Milles seisneb uuringute põhjal Prialti kasulikkus?
English: In the third study, there was a trend for Prialt to be more effective than placebo, with the VASPI score changing from 81 mm before treatment to 68 mm in patients receiving Prialt and to 74 mm in patients receiving placebo.
Estonian: Kolmandas uuringus kaldus Prialt olema platseebost efektiivsem, sest VASPI-väärtus alanes ravieelsest tasemest 81 mm Prialti saanud patsientidel 68 mm-ni ja platseebot saanud patsientidel 74 mm-ni.
English: Because the number of patients who have long-term pain that requires painkillers to be injected directly into the spine is low, the disease is considered ‘rare', and Prialt was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 July 2001.
Estonian: Et selliseid valuvaigisteid vajavaid kroonilise valuga patsiente on vähe ja see haigus esineb harva, nimetati Prialt 9. juulil 2001 harvikravimiks.
English: Treatment with Prialt should only be carried out by a doctor who has experience in the intrathecal dosing of medicines.
Estonian: Ravi Prialtiga tohib teha üksnes ravimite intratekaalse manustamise kogemusega arst.
English: Prialt must not be used in patients at the same time as intrathecal chemotherapy (medicines to treat cancer that are injected into the spinal canal).
Estonian: Prialti ei tohi kasutada patsiendid, kes saavad samal ajal intratekaalset keemiaravi (lülisambakanalisse süstitavaid vähiravimeid).
English: Prialt was more effective than placebo in the first two studies.
Estonian: Esimeses kahes uuringus oli Prialt platseebost efektiivsem.
English: The active substance in Prialt, ziconotide, is a copy of a natural substance called omega-conopeptide, which is found in the venom of a type of sea snail.
Estonian: Prialti toimeaine sikonotiid on teatud mereteo mürgis leiduva loodusliku aine oomega-konopeptiidi analoog.
English: By blocking the flow of calcium into the nerve cells, ziconotide interferes with the transmission of pain signals within the spine.
Estonian: Blokeerides kaltsiumiioonide pääsu närvirakkudesse, takistab sikonotiid valusignaalide edastamist lülisambas ja aitab sel teel valu leevendada.
English: The starting dose of Prialt is 2.4 micrograms per day.
Estonian: Prialti algannus on 2,4 µg ööpäevas.
English: How is Prialt used?
Estonian: Kuidas Prialti kasutatakse?
English: Ziconotide acts by blocking special pores called calcium channels on the surface of the nerve cells that transmit the pain signals.
Estonian: Selle toime seisneb valusignaale edastavate närvirakkude pinnal olevate kaltsiumikanalite blokeerimises.
English: Prialt is used to treat severe, long-term pain in adults who need a painkiller by intrathecal injection (injection into the space that surrounds the spinal cord and the brain).
Estonian: Prialti kasutatakse raske kroonilise (pikaajalise) valu raviks täiskasvanud patsientidel, kes vajavad intratekaalset valuvaigistit (süstitakse lülisambakanalisse).
English: How does Prialt work?
Estonian: Kuidas Prialt toimib?
English: What is Prialt used for?
Estonian: Milleks Prialti kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Prialt on retseptiravim.
English: How has Prialt been studied?
Estonian: Kuidas Prialti uuriti?
English: London, 23 April 2009 Doc.
Estonian: London, 23. aprill 2009 Dok.
English: Ref. EMEA/196121/2009
Estonian: viide EMEA/316920/2009
English: The company had initiated an appeal process, but this had not yet finished.
Estonian: Ettevõte oli alustanud apellatsioonimenetlust, mis veel kestis.
English: What is Ixempra?
Estonian: Mis on Ixempra?
English: If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.
Estonian: Kui osalete kliinilises uuringus või eriloaga kasutamise programmis ja vajate oma ravi kohta lisateavet, pöörduge palun arsti poole, kes teile ravi määras.
English: International non-proprietary name (INN): ixabepilone
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): iksabepiloon
English: The main measure of effectiveness was the number of patients whose cancer responded to treatment.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kelle vähk allus ravile.
English: With the skeleton unable to change, the cancer cells cannot divide and they eventually die.
Estonian: Kui raku sisetoes ei saa muutuda, ei saa vähirakud jaguneda ja lõpuks hävivad.
English: In particular, the Committee was concerned over the risk of patients developing neuropathy (damage to nerve cells), which was a severe and common side effect in patients taking the medicine.
Estonian: Eelkõige tegi komiteele muret oht, et patsientidel tekib neuropaatia (närvirakkude kahjustus), mis oli tõsine ja sage kõrvalnäht ravimit võtvatel patsientidel.
English: On 18 March 2009, Bristol-Myers Squibb Pharma EEIG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Ixempra, for the treatment of locally advanced or metastatic breast cancer.
Estonian: 18. märtsil 2009 teatas Bristol-Myers Squibb Pharma EEIG ametlikult inimravimite komiteele oma soovist võtta tagasi lokaalselt edasiarenenud või metastaatilise rinnavähi raviks mõeldud ravimi Ixempra müügiloa taotlus.
English: Questions and answers on the withdrawal of the marketing authorisation for Ixempra
Estonian: Teave müügiloa tagasivõtmise kohta Ixempra
English: The first study looked at Ixempra given on its own in 128 women, but did not compare it with any other treatment.
Estonian: Esimeses uuringus uuriti ainsa ravimina manustatud Ixempra toimet 128 naisel, aga seda ei võrreldud teiste ravimitega.
English: Ixempra has been studied in three main studies involving women with locally advanced or metastatic breast cancer who had been treated with a number of other anticancer medicines in the past.
Estonian: Ixemprat uuriti kolmes põhiuuringus, milles osalesid lokaalselt edasiarenenud või metastaatilise rinnavähiga naised, kes olid varem saanud ravi mitme muu vähiravimiga.
English: It was to be used in combination with capecitabine (another anticancer medicine) when previous treatment with cytotoxic medicines (medicines that kill cells that are dividing, such as cancer cells) had failed.
Estonian: Seda kavatseti kasutada kombineerituna kapetsitabiiniga (teine vähiravim), kui eelnenud ravi tsütotoksiliste (jagunevaid rakke, näiteks vähirakke, hävitav ravim) ravimitega ei ole tulemust andnud.
English: Ixabepilone is expected to block the ability of cells to modify the internal ‘skeleton' that they need to divide and multiply.
Estonian: Eeldatavasti blokeerib iksabepiloon rakkude võimet modifitseerida raku sisetoest, mis on vajalik jagunemiseks ja paljunemiseks.
English: The CHMP had given a negative opinion and did not recommend a marketing authorisation for Ixempra for the treatment of locally advanced or metastatic breast cancer.
Estonian: Inimravimite komitee oli andnud negatiivse arvamuse ja ei soovitanud anda Ixemprale müügiluba ravimi kasutamiseks lokaalselt edasiarenenud või metastaatilise rinnavähi raviks.
English: Therefore, at the time of the withdrawal, the CHMP's view was that the benefits of Ixempra in the treatment of breast cancer did not outweigh the identified risks.
Estonian: Seepärast oli inimravimite komitee taotluse tagasivõtmise ajal arvamusel, et Ixempra kasulikkus rinnavähi ravis ei ületa tuvastatud riske.
English: Ixabepilone is also expected to affect non-cancer cells such as nerve cells, which could cause side effects.
Estonian: Eeldatavasti mõjutab iksabepiloon peale vähirakkude ka muid rakke, näiteks närvirakke, mis võib põhjustada kõrvalmõjusid.
English: Ixempra is a medicine that contains the active substance ixabepilone.
Estonian: Ixempra on ravim, mis sisaldab toimeainena iksabepilooni.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials with Ixempra and that patients receiving Ixempra as part of a compassionate use programme will continue to receive the medicine.
Estonian: Ettevõte teatas inimravimite komiteele, et praegu Ixempra kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele tagasivõtmine mõju ei avalda ja patsiendid, kes saavad Ixemprat eriloaga kasutamise programmi raames, saavad seda ravimit ka edaspidi.
English: Ixempra was expected to be used to treat breast cancer that is locally advanced or metastatic (when the tumour is large or has begun to spread within the body).
Estonian: Ixemprat kavatseti kasutada lokaalselt edasiarenenud või metastaatilise (kasvaja on suur või on hakanud levima mujale organismi) rinnavähi raviks.
English: What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes using Ixempra?
Estonian: Mis on tagasivõtmise mõju praegu Ixempra kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
English: How is Ixempra expected to work?
Estonian: Milline on Ixempra eeldatav toime?
English: The main measures of effectiveness were how long the patients lived without their cancer getting worse and how long they survived.
Estonian: Efektiivsuse põhinäitajad olid ajavahemik, mille jooksul patsiendi vähk ei arenenud edasi, ja patsientide elulemus.
English: The effects of Ixempra were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Ixempra toimet muude katsetega.
English: It was to be available as a powder and a solvent to be made up into a solution for infusion (drip into a vein).
Estonian: Seda kavatseti turustada pulbri ja lahustina infusioonilahuse valmistamiseks (veeni tilgutamiseks).
English: The CHMP was concerned that Ixempra's benefits in terms of increasing the time until the cancer got worse did not outweigh the concerns over the medicine's safety.
Estonian: Inimravimite komitee ettevaatlikkuse põhjuseks oli see, et Ixempra kasulikkus vähi edasiarenemise edasilükkamise seisukohalt ei kaalunud üles kahtlusi ravimi ohutuse suhtes.
English: The active substance in Ixempra, ixabepilone, is a cytotoxic medicine that belongs to a group of medicines called the ‘epothilones'.
Estonian: Ixempra toimeaine iksabepiloon on tsütotoksiline ravim, mis kuulub epotiloonide ravimiklassi.
English: The other two studies compared the effects of capecitabine given on its own with the effects of Ixempra given in combination with capecitabine in a total of 1,973 women.
Estonian: Kahes ülejäänud uuringus (kokku 1973 naist) võrreldi ainsa ravimina manustatud kapetsitabiini toimet ja koos kapetsitabiiniga manustatud Ixempra toimet.
English: What was Ixempra expected to be used for?
Estonian: Milleks kavatseti Ixemprat kasutada?
English: OTHER SPECIAL WARNING(S), IF NECESSARY For single use only.
Estonian: TEISED ERIHOIATUSED (VAJADUSEL) Ainult ühekordseks kasutamiseks.
English: This dose might be repeated if needed.
Estonian: Vajaduse korral võib seda annust korrata.
English: Other medicines and OPTISON Tell your doctor if you are taking or have recently taken any other medicines.
Estonian: Muud ravimid ja OPTISON Teatage oma arstile, kui te kasutate või olete hiljuti kasutanud mis tahes muid ravimeid.
English: * Reactions for which no frequency rate can be provided due to lack of clinical trial data have been classified as “Not known”.
Estonian: * Reaktsioonid, mille esinemissagedust ei saa hinnata kliiniliste uuringute andmete puudumise tõttu, on liigitatud kui "Teadmata".
English: This leaflet is available in all EU/EEA languages on the European Agency website.
Estonian: See infoleht on kõigis EL/EMPi keeltes Euroopa Ravimiameti kodulehel.
English: Date of latest renewal: 12 June 2008
Estonian: Müügiloa viimase uuendamise kuupäev: 12. juuni 2008
English: The following instructions should be followed:
Estonian: Toimige järgnevalt:
English: Unopened vial in the outer packaging: 2 years.
Estonian: Avamata viaal pakendis: 2 aastat.
English: The clinical relevance of this finding is unknown.
Estonian: Selle leiu kliiniline tähendus ei ole teada.
English: INFORMATION IN BRAILLE Justification for not including Braille accepted 17.
Estonian: INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) Põhjendus Braille mitte lisamiseks 17.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 18 May 1998
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 18. mai 1998
English: OPTISON must not be mixed with other medicinal products.
Estonian: OPTISON'i ei tohi segada teiste ravimitega.
English: The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c (7) of Directive 2001/83/EC and published on the European medicines web-portal.
Estonian: Müügiloa hoidja peab esitama asjaomase ravimi perioodilisi ohutusaruandeid kooskõlas direktiivi 2001/83/EÜ artikli 107c punktis 7 sätestatud ja Euroopa ravimite veebiportaalis avaldatud liidu kontrollpäevade loetelu (EURD loetelu) nõuetega.
English: Pharmacotherapeutic group: Ultrasound contrast medium, ATC Code: V08D A01
Estonian: Farmakoterapeutiline rühm: ultraheliuuringu kontrastaine, ATC kood: V08D A01
English: This study did not assess the effect of OPTISON on visualisation of cardiac or pulmonary structures.
Estonian: See uuring ei hinnanud OPTISON-i mõju südame või pulmonaalsete struktuuride visualiseerimisele.
English: However, because OPTISON is based on human albumin (the main protein in our blood), it is highly unlikely that it will have any harmful effects in pregnancy.
Estonian: Kuna OPTISON põhineb inimese albumiinil (põhiline meie veres sisalduv valk), on selle kahjulik toime rasedusele väga ebatõenäoline.
English: You can also report side effects directly via the national reporting system.
Estonian: Kõrvaltoimetest võite ka ise teavitada riikliku teavitussüsteemi kaudu.
English: Like all medicines, OPTISON can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka see ravim põhjustada kõrvaltoimed, kuigi kõigil neid ei teki.
English: What OPTISON looks like and contents of the pack
Estonian: Kuidas OPTISON välja näeb ja pakendi sisu
English: In two uncontrolled studies including a total of 42 children and adolescents, aged 8 months to 19 years, the safety profile appeared to be similar to that seen in adults.
Estonian: Kahes kontrollrühmata uuringus, kus osales kokku 42 last ja noorukit (vanusevahemik 8 kuud...19 aastat), sarnanes ohutuse profiil täiskasvanute omaga.
English: The disposition and elimination of the albumin microspheres have not been studied in humans.
Estonian: Albumiini mikrosfääride jaotumist ja eritumist inimestel ei ole uuritud.
English: Vials are intended for single use only.
Estonian: Viaalid on mõeldud ühekordseks kasutamiseks.
English: Care should therefore be exercised.
Estonian: Seepärast tuleb olla ettevaatlik.
English: Systemic haemodynamic parameters and ECGs were also evaluated.
Estonian: Hinnati ka süsteemse hemodünaamika parameetreid ja EKG-sid.
English: Homogenous white suspension after resuspension.
Estonian: Pärast resuspendeerimist saadakse homogeenne valge suspensioon.
English: A dose of 3.0 ml is usually sufficient, but some patients may need higher doses.
Estonian: 3,0 ml on harilikult piisav annus, kuid mõned patsiendid võivad vajada suuremat annust.
English: - Any pressure instability within the vial should be avoided since it may cause disruption of microspheres and loss of contrast effect.
Estonian: - Rõhu kõikumist pudelis tuleb vältida, sest see võib põhjustada mikrosfääride lagunemise ja kontrastaine toime kadumise.
English: Resuspend before use.
Estonian: Enne kasutamist resuspendeerida.
English: Intravenous use.
Estonian: Intravenoosseks manustamiseks.
English: The experience of OPTISON in severely ill patients is limited.
Estonian: OPTISON'i kasutamise kogemus raskes üldseisundis patsientidel on piiratud.
English: • Eosinophilia (increased number of a type of white blood cells in the blood)
Estonian: • eosinofiilia (teatavat liiki valgeliblede arvu suurenemine veres)
English: A separate syringe should be used.
Estonian: Tuleb kasutada eraldi süstalt.
English: Store upright in a refrigerator (2°C - 8°C).
Estonian: Hoida püstiasendis, külmkapis (2…8°C).
English: OPTISON could be repeatedly administered, however, the clinical experience is limited.
Estonian: OPTISON'i võib manustada korduvalt, vastav kliiniline kogemus on siiski piiratud.
English: OPTISON should be used in these categories of patients only after careful consideration and monitored closely during and after administration.
Estonian: Niisugustel haigetel tuleb OPTISON'i kasutada ainult pärast hoolikat kaalumist ja haigeid tuleb manustamise ajal ja pärast manustamist tähelepanelikult jälgida.
English: Higher doses produce greater contrast effect of longer duration.
Estonian: Suuremad annused tekitavad kauem püsiva tugevama kontrasteerumise.
English: This also applies to any unknown or emerging viruses or other types of infections.
Estonian: See kehtib ka tundmatute või välja ilmuvate viiruste ja teist tüüpi nakkushaiguste kohta.
English: The primary route of elimination of radioactivity was the urine.
Estonian: Põhiline radioaktiivsuse eritumine toimus uriiniga.
English: What you need to know before you use OPTISON
Estonian: Mida on vaja teada enne OPTISON'I kasutamist
English: OTHER GE Healthcare
Estonian: MUU GE Healthcare
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/065/001 EU/1/98/065/002 13.
Estonian: MÜÜGILOA NUMBER(NUMBRID) EU/1/98/065/001 EU/1/98/065/002 13.
English: Storage at room temperature (up to 25°C) for 1 day is acceptable.
Estonian: Toatemperatuuril (kuni 25°C) võib hoida ühe päeva.
English: How to use OPTISON
Estonian: Kuidas OPTISON'i kasutada
English: In the Phase I trial, healthy volunteers have received up to 44.0 ml of OPTISON and experienced no significant adverse events.
Estonian: I faasi uuringutes manustati tervetele vabatahtlikele kuni 44,0 ml OPTISON'i ja arvestatavaid kõrvalnähte ei tekkinud.
English: BATCH NUMBER Lot 14.
Estonian: PARTII NUMBER Partii nr: 14.
English: Low mechanical index was used for ultrasound imaging.
Estonian: Ultraheliuuringutel kasutati madalat mehaanilist indeksit.
English: What OPTISON is and what it is used for
Estonian: Mis ravim on OPTISON ja milleks seda kasutatakse
English: Use during anaesthesia with halothane and oxygen has not been studied.
Estonian: OPTISON'i kasutamist halotaani ja hapnikuga läbi viidavas üldanesteesias ei ole uuritud.
English: - Use the suspension within 30 minutes after withdrawal.
Estonian: - Kasutage suspensiooni poole tunni jooksul pärast süstlasse tõmbamist.
English: No clinically important pulmonary haemodynamic, systemic haemodynamic, or ECG changes were observed.
Estonian: Kliiniliselt olulisi pulmonaalse hemodünaamika, süsteemse hemodünaamika ega EKG muutusi ei täheldatud.
English: Information obtained from a preclinical study in rats with 125I-labelled albumin microspheres indicated that microspheres were rapidly cleared from the circulation, and radio-labelled microspheres, albumin shells and 125I were taken up primarily in the liver.
Estonian: Prekliinilistes uuringutes rottidel 125I märgistatud albumiiniga leiti, et mikrosfäärid eemaldati vereringest kiiresti ja märgistatud mikrosfäärid, albumiin ja 125I kogunesid põhiliselt maksa.
English: The total dose should not exceed 8.7 ml per patient.
Estonian: Koguannus ei tohiks ületada 8,7 ml.
English: OPTISON contrast echocardiography should be accompanied by ECG monitoring.
Estonian: Kontrastehhograafial OPTISON'iga peaks lisaks rakendama EKG jälgimist.
English: OPTISON contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-free”.
Estonian: OPTISON sisaldab vähem kui 1 mmol naatriumi (23 mg) annuse kohta, see tähendab, et see on põhimõtteliselt naatriumivaba.
English: What OPTISON is and what it is used for What you need to know before you use OPTISON How to use OPTISON
Estonian: Mis ravim on OPTISON ja milleks seda kasutatakse Mida on vaja teada enne OPTISON'i kasutamist Kuidas OPTISON'i kasutada Võimalikud kõrvaltoimed
English: Although these biological side effects have not been reported in humans, the use of a low mechanical index and enddiastolic triggering is recommended.
Estonian: Kuigi puuduvad andmed bioloogiliste kõrvaltoimete ilmnemisest inimesel, soovitatakse kasutada madalat mehaanilist indeksit ja kontrastaine vallandamist diastoli lõpus.
English: OPTISON improves the visualization of the inner cardiac walls in patients where the walls are difficult to see.
Estonian: OPTISON võimaldab näha selgemini südame siseseinu patsientidel, kellel need seinad on halvasti nähtavad.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER GE Healthcare AS, Nycoveien 1, 0485 Oslo, Norway 12.
Estonian: MÜÜGILOA HOIDJA NIMI JA AADRESS GE Healthcare AS, Nycoveien 1, 0485 Oslo, Norra 12.